Verismo Therapeutics has reported encouraging first-in-human findings for SynKIR-310, an investigational CD19-targeted cell therapy, showing an 80% objective response rate and a 60% complete response rate among five evaluable patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Announced on November 4, 2026, the preliminary results also showed no reported cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome or dose-limiting toxicity among six patients treated across the first two dose levels.
The findings come from CELESTIAL-301, an ongoing Phase 1 clinical trial evaluating Verismo’s proprietary multi-chain killer immunoglobulin-like receptor chimeric antigen receptor T-cell platform, known as KIR-CAR. The company will present updated results from the first three dose cohorts at the 68th American Society of Hematology Annual Meeting in New Orleans on December 13, 2026. Those results will include additional clinical and pharmacokinetic and pharmacodynamic information that has not yet been fully disclosed.
The early dataset is notable because conventional CAR-T therapies can cause serious inflammatory complications, including cytokine release syndrome and neurological toxicity. However, observing no such events in six treated patients does not establish that SynKIR-310 eliminates these risks or is safer than approved CD19-targeted CAR-T products. The 80% response rate also comes from only five evaluable individuals, making larger patient numbers and longer follow-up essential before conclusions about efficacy and durability can be drawn.
What did the first-in-human CELESTIAL-301 trial show about SynKIR-310’s antitumour activity?
CELESTIAL-301 is an ongoing Phase 1 clinical investigation, registered as NCT06544265, evaluating SynKIR-310 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma following at least two previous lines of treatment. The study is designed to assess the safety and clinical potential of a novel cellular immunotherapy in a population whose disease has returned or failed to respond adequately to earlier treatment.
Among the first six patients treated across dose cohorts one and two, five were evaluable for response at the reported analysis. Four of these five patients experienced an objective response, corresponding to a response rate of 80%. Three achieved a complete response, equivalent to 60% of the evaluable population.
These findings provide an early indication that the investigational cells can produce antitumour activity in patients with advanced lymphoma. Complete response is particularly relevant because it indicates that no detectable disease remains according to the applicable response assessment criteria. However, complete response does not establish permanent eradication of cancer or guarantee that relapse will not occur.
The distinction between treated and evaluable patients is important. The response percentages use five patients as the denominator, while the reported safety observations cover all six treated individuals. Presenting the 80% result without the underlying patient count would exaggerate the statistical strength of the finding.
The company has not disclosed detailed baseline characteristics, prior therapies or the lymphoma subtypes represented among all six participants in its November announcement. Those details will be important for understanding how challenging the treated population was and how the findings compare with existing therapeutic options.
Why is a 60% complete response rate encouraging but not definitive evidence of efficacy?
Complete responses can be meaningful in relapsed or refractory lymphoma, particularly when patients have limited remaining treatment options. A therapy that produces deep tumour reduction after several previous treatments may warrant further investigation. This provides a rationale for continuing SynKIR-310 development.
However, a three-patient complete response count offers limited statistical precision. If one additional patient had responded or failed to respond, the calculated percentage would change substantially. The small sample therefore cannot reliably estimate the response rate that might be observed in a broader clinical population.
The Phase 1 study also lacks a randomised control group in the initial reported analysis. Consequently, Verismo cannot establish that SynKIR-310 is superior to an approved CD19-directed therapy or another treatment available to the same patients. Differences in disease subtype, previous treatment and baseline health could influence observed responses.
Response duration is another critical consideration. Some lymphoma treatments produce substantial initial tumour reduction but are followed by relapse. A new cell therapy must demonstrate that responses remain meaningful over time and that disease control justifies the treatment-related risks.
The next data release should provide information about additional patients and follow-up. If favourable responses are reproduced across subsequent dose cohorts, confidence in the treatment’s biological activity may strengthen. Nevertheless, larger studies would still be needed before regulatory-level efficacy claims could be supported.
What does the 12-month complete response reveal about potential treatment durability?
Verismo reported that the median duration of response among patients achieving a complete response had not been reached at the time of analysis. It also disclosed that one patient remained in complete response at the 12-month assessment following treatment. These observations suggest that at least some of the initial antitumour activity may persist beyond the early treatment period.
However, median duration of response not being reached can have several explanations. In a small dataset, there may not yet have been enough progression or relapse events to calculate the median reliably. Follow-up duration may also vary between participants, particularly during an ongoing dose-escalation study.
The finding should therefore not be interpreted as proof that complete responses are permanent. It also does not establish a median duration exceeding 12 months for every responding patient. The publicly disclosed evidence identifies one continuing complete response at that time point rather than a mature long-term durability dataset.
Longer follow-up will be particularly important because cell therapies are often developed with the objective of producing sustained antitumour effects. Researchers will need to assess how long engineered cells remain detectable, whether they retain functional activity and how these characteristics relate to disease control.
The December presentation is expected to include pharmacokinetic and pharmacodynamic information. These analyses may help investigators understand how the cellular product behaves after administration, but their clinical implications will depend on the accompanying response and safety observations.
Why is the absence of cytokine release syndrome an important early safety finding?
Cytokine release syndrome is a recognised complication of several immune cell therapies, including conventional CAR-T treatments. It can develop when activated immune cells release inflammatory mediators, producing symptoms ranging from fever and fatigue to potentially life-threatening cardiovascular or respiratory complications. Its severity depends on the therapy, patient characteristics and biological response.
Verismo reported no cytokine release syndrome of any grade among the six patients treated across the first two SynKIR-310 dose levels. The absence of reported events is encouraging because the therapy was developed around a signalling architecture intended to modify the way engineered T cells become activated. The finding is consistent with the company’s broader objective of reducing excessive inflammatory activation.
However, six patients are insufficient to exclude clinically important risks. A complication that occurs relatively infrequently might not appear in such a small group. Higher doses or treatment of patients with different disease burdens could also produce different adverse-event patterns.
The study’s early dose-escalation design adds another limitation. Initial cohorts often receive relatively low doses to assess safety before further escalation. The absence of toxicity at those levels does not establish that a later dose will have the same profile.
Verismo’s data therefore support continued dose evaluation rather than a conclusion that cytokine release syndrome has been eliminated. The forthcoming third-cohort findings will be especially relevant to understanding whether the favourable safety observations persist with additional exposure.
What does the absence of ICANS and dose-limiting toxicity mean for SynKIR-310?
Immune effector cell-associated neurotoxicity syndrome, known as ICANS, is another important complication associated with certain cellular immunotherapies. It can involve confusion, language difficulties, altered consciousness and, in severe cases, neurological complications requiring intensive medical care. The risk is one reason CAR-T treatment often requires specialised monitoring.
None of the six patients in the first two SynKIR-310 cohorts experienced reported ICANS of any grade. Verismo also observed no dose-limiting toxicities during the evaluated treatment period. These findings suggest that the initial doses were tolerated sufficiently to support continued clinical investigation.
However, a dose-limiting toxicity assessment generally concerns a defined observation window and prespecified criteria. The absence of such events does not mean that every adverse reaction has been excluded or that longer-term complications cannot emerge. Cell therapies may produce delayed toxicities that require extended follow-up.
The company has not published a complete table of all treatment-emergent adverse events in the November announcement. Consequently, it would be inappropriate to describe SynKIR-310 as having no side effects or to assume that every patient experienced an uncomplicated treatment course.
Safety evaluation must also consider cytopenias, infections and other complications that may occur in heavily pretreated lymphoma patients. The relationship between adverse events and the cellular therapy must be assessed within the study.
The early findings are encouraging, but a reliable comparison with conventional CAR-T treatment will require substantially more data.
How does Verismo’s multi-chain KIR-CAR platform differ from conventional CAR-T technology?
Conventional CAR-T therapies typically use engineered receptors that combine antigen recognition and intracellular activation functions within a single receptor structure. These designs often rely on CD3-zeta signalling together with one or more co-stimulatory domains to activate T cells after they bind a cancer-associated antigen.
Verismo’s KIR-CAR platform uses a different architecture derived from killer immunoglobulin-like receptor signalling found in natural killer cells. It separates the antigen-binding receptor from the intracellular activation machinery through a multi-chain system involving KIR-related components and the DAP12 adaptor protein. The platform is designed to activate T cells independently of conventional CD3 signalling.
The company believes this architecture may reduce unnecessary background activation and premature T-cell exhaustion. T-cell exhaustion refers to a state in which immune cells lose some functional capacity after prolonged stimulation. It represents one potential obstacle to sustaining antitumour responses.
However, the biological consequences of receptor architecture cannot be established from design alone. A signalling system that produces lower inflammatory cytokine levels in laboratory experiments may behave differently in patients. Its activity must be evaluated alongside tumour control, cell persistence and treatment-related complications.
The clinical value of KIR-CAR will depend on whether the platform combines strong antitumour activity with acceptable safety across sufficiently large patient populations. The initial SynKIR-310 findings provide preliminary human evidence but do not yet validate the complete platform.
Why could three outpatient-treated patients matter for the future of CAR-T delivery?
Verismo disclosed that three of the six patients treated during the first two cohorts received SynKIR-310 in an outpatient setting. This is potentially relevant because conventional CAR-T treatment can require substantial specialist monitoring, and some patients need hospital admission to manage inflammatory or neurological complications.
Outpatient administration may reduce certain costs and inconvenience associated with treatment. It could also potentially expand access if patients can be monitored safely outside the hospital. However, an outpatient treatment model requires reliable emergency support and clear procedures for managing complications should they occur.
The reported three patients demonstrate that outpatient administration was feasible within the selected clinical circumstances. However, the company did not disclose complete details concerning subsequent hospital admissions, monitoring requirements or the criteria used to select patients for outpatient treatment.
The absence of reported cytokine release syndrome and ICANS in the early cohort may support further investigation of this approach. Nevertheless, the small sample cannot establish that routine outpatient treatment will be safe across different institutions or higher dose levels.
A commercially successful outpatient strategy would need to preserve treatment effectiveness while providing appropriate safety oversight. The practical benefit would depend on the complete care pathway, not simply on where the cells are infused.
What will Verismo present at the December 2026 American Society of Hematology meeting?
SynKIR-310 has been selected for an oral presentation at the 68th American Society of Hematology Annual Meeting and Exposition in New Orleans. Michael Tees of Colorado Blood Cancer Institute is scheduled to present the clinical findings on December 13 at 5:45 p.m. local time. The presentation is identified as abstract 708 within the session covering early-phase cellular immunotherapies and toxicities.
The December update will include additional results extending through dose cohort three. Verismo also plans to present pharmacokinetic and pharmacodynamic analyses intended to provide information about cellular exposure and biological activity. The company has stated that its fuller clinical readout will be released at the time of the presentation.
These future results should not be described as already known. The November announcement provides numerical efficacy and safety findings only for the first two cohorts. The third-cohort response rate, adverse events and dose-related patterns remain undisclosed.
The additional dataset could help determine whether antitumour activity continues at higher doses and whether the absence of important inflammatory complications persists. Investigators may also be able to examine relationships between treatment exposure and response.
However, the programme will remain an early-phase study even after the December presentation. A favourable expansion of the dataset would support continued development but would not establish regulatory approval or definitive superiority over licensed CAR-T therapies.
Why is Verismo developing a CD19/CD20 dual-targeted KIR-CAR alongside SynKIR-310?
CD19 is an established therapeutic target in B-cell malignancies, and several approved CAR-T products use CD19-directed recognition. However, some patients relapse after treatment, including cases in which tumour cells lose or reduce expression of the targeted antigen. This creates interest in approaches recognising more than one B-cell marker.
Verismo is developing a preclinical CD19/CD20 dual-targeted KIR-CAR construct intended to address antigen heterogeneity. CD20 is another established B-cell-associated protein, providing an additional potential recognition mechanism. The objective is to make it more difficult for tumour populations to evade treatment through reduced expression of one antigen alone.
At ASH 2026, Nora Yucel will present preclinical research involving the dual-targeted construct. Verismo says the experimental system demonstrated activity against antigen-heterogeneous B-cell lymphoma models with reduced cytokine secretion compared with a selected single-chain benchmark.
These findings provide a rationale for further research but do not demonstrate clinical effectiveness. The dual-targeted candidate is separate from SynKIR-310, which remains a CD19-targeted therapy. The response rates observed in the CELESTIAL-301 trial therefore should not be attributed to the newer dual-targeting construct.
The company also describes the platform as potentially adaptable to both ex vivo and in vivo gene-delivery approaches. However, the announcement does not establish an approved in vivo KIR-CAR treatment or confirm that the dual-targeted construct has entered human clinical testing.
What does the preclinical comparison with conventional single-chain CAR-T designs establish?
Verismo will present a second scientific poster comparing its multi-chain SynKIR-310 architecture with selected single-chain CD19 CAR-T designs. The preclinical findings suggest that the KIR-CAR construct achieved deeper tumour control and reduced cytokine production in the evaluated experimental systems.
These observations are relevant because treatment efficacy and inflammatory toxicity are two important considerations in CAR-T development. A platform producing strong tumour control with less excessive immune activation could offer meaningful advantages if the effects translate into human patients.
However, the choice of comparator construct and experimental model can influence preclinical outcomes. A favourable result against one laboratory benchmark does not establish superiority over all commercially authorised CAR-T medicines. Differences in manufacturing, cell composition and clinical dosing also complicate extrapolation.
The combined clinical and preclinical findings suggest that Verismo is investigating whether its signalling architecture can create a more favourable balance between tumour elimination and immune activation. Nevertheless, that hypothesis remains incompletely tested.
The most persuasive evidence will come from larger patient studies evaluating response durability, serious adverse events and clinical outcomes under consistent treatment conditions. Until then, platform comparisons should remain explicitly preclinical.
How could SynKIR-310 fit into the competitive B-cell lymphoma treatment market?
The treatment landscape for relapsed or refractory B-cell lymphoma already includes several approved CD19-directed CAR-T therapies, bispecific antibodies and other targeted medicines. These products have demonstrated meaningful responses in selected patients, although relapse, toxicity and access remain significant challenges.
A new cell therapy must establish a differentiated clinical profile to justify adoption. Potential advantages could involve response durability, reduced inflammatory complications or a less resource-intensive administration pathway. Verismo’s early findings address these areas but do not yet provide sufficient evidence for a comparative claim.
The small CELESTIAL-301 dataset also makes it difficult to determine which lymphoma subtypes might benefit most. Clinical outcomes can vary considerably across different B-cell malignancies and prior treatment histories. Larger cohorts will be needed to identify the most appropriate patient population.
Manufacturing considerations will be equally important. Autologous cellular therapies require collection, engineering and processing of patient-derived cells, creating logistical challenges and costs. The potential benefits of a new receptor platform must therefore be assessed alongside production reliability and treatment availability.
Verismo is a privately operated clinical-stage biotechnology developer associated with South Korea’s HLB group. It has not disclosed a revenue forecast or commercial launch timetable for SynKIR-310. The programme remains focused on generating evidence to support further development.
What must SynKIR-310 demonstrate before its early results can support larger clinical trials?
The first requirement is reproducible antitumour activity across additional dose cohorts. Four responses among five evaluable patients are promising, but the percentage is highly sensitive to individual outcomes. A larger dataset will help determine whether the initial response pattern is consistent.
The second requirement is durable disease control. Complete responses may be particularly meaningful if they persist, but longer observation is necessary to establish the timing of relapse or progression. The forthcoming clinical data should provide greater insight into response duration.
Safety remains equally important. The absence of reported cytokine release syndrome, ICANS and dose-limiting toxicity in six patients is encouraging, but uncommon events may emerge as enrolment expands. Investigators must also assess other acute and delayed complications associated with cellular therapy.
The third-cohort data scheduled for December will provide another opportunity to examine these questions. Pharmacokinetic and pharmacodynamic findings could help researchers understand whether receptor design influences cellular activity and persistence in the intended manner.
Verismo Therapeutics has generated a notable early clinical signal for its novel multi-chain CAR-T platform, including three complete responses and no reported major inflammatory syndromes among the first six treated patients. However, the data remain preliminary and cannot yet establish a durable efficacy or safety advantage over existing treatments.
The December ASH presentation will be the next important milestone. Its significance will depend on whether additional patients reinforce the initial findings while providing a clearer understanding of dose response, treatment persistence and adverse-event risk.
